Lycia Therapeutics raises $317.5 million in upsized Nasdaq IPO and jumps 66.67% on debut

Lycia Therapeutics, a clinical-stage South San Francisco drug developer founded on the research of Nobel laureate Carolyn Bertozzi, has completed one of the most closely watched biotechnology listings of the autumn 2026 IPO window, pricing an upsized offering and then watching its shares surge well past the offer price in their first session on the Nasdaq Global Select Market.

The company sold 17,640,000 shares of common stock at $18.00 each, the top of a marketed range of $16.00 to $18.00, to raise gross proceeds of approximately $317.5 million before underwriting discounts, commissions and other expenses. All of the shares in the offering were sold by Lycia itself rather than by existing holders, and the company granted the underwriters a 30-day option to buy up to an additional 2,646,000 shares at the IPO price less discounts and commissions.

The stock, which trades under the symbol LYCA, first printed at $28.55 at 11:54 a.m. Eastern time on Friday, October 23, 2026, on volume of 229,921 shares, and finished the session at $30.00. That close represented a gain of $12.00, or 66.67%, from the IPO price, on volume of about 2.28 million shares. At the $18.00 offer price the company carried a market capitalisation of $990.62 million, while the closing price implied a market value of roughly $1.65 billion.

Lycia is developing medicines that degrade disease-causing extracellular proteins rather than simply blocking them, an approach it pursues through its LYTAC (Lysosomal Targeting Chimera) platform, which is based on Bertozzi's work at Stanford University, where she is a professor of chemistry and an HHMI investigator. The company has since advanced the platform into what it calls cataLYTAC degraders, designed for repeated catalytic elimination of disease-causing proteins. Its pipeline is initially aimed at autoimmune, inflammatory and allergic disease and includes LCA-0061, a degrader of immunoglobulin E in a Phase 1 trial, LCA-0062, a second IgE candidate in IND-enabling activities, and LCA-0321, which is in Phase 1 testing in Graves' disease.

Key Facts

Renaissance Capital reported on October 23, 2026, that the offering was 27% larger than the company's original plan at the midpoint of the original terms, after Lycia lifted the deal to 17.6 million shares from the 14.7 million contemplated in its prospectus. The IPO desk put the fully diluted market capitalisation at pricing at $1.1 billion, and described Lycia as a Phase 1 biotech developing protein degraders for food allergy and Graves' disease.

IPOScoop reported on October 22, 2026, that Lycia upsized the deal at pricing to 17.64 million shares from 14.7 million and priced it at $18.00, the top of its range, to raise $317.52 million on the night of Thursday, October 22, 2026. In an update after the first session, IPOScoop recorded the opening trade at $28.55, up $10.55 or 58.61%, and the closing print at $30.00, up $12.00 or 66.67%, on volume of about 2.28 million shares.

Reuters reported on October 23, 2026, that Lycia's stock jumped 27.5% in its Nasdaq debut after the upsized $317.5 million US initial public offering, opening at $28.55 a share against an IPO price of $18.00. That figure was an intraday snapshot taken after the 11:54 a.m. EDT first trade, and the same report identified Lycia as founded by Bertozzi, a Nobel Prize winner, and as developing medicines for autoimmune, inflammatory and allergic diseases, with Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities acting as joint lead bookrunners. Reuters framed the listing inside the autumn 2026 IPO window, which it said has been dominated by biotechnology while higher borrowing costs and unstable markets held back other sectors, and which has also featured heavily publicised postponements as investors grew more selective.

BioSpace reported on October 22, 2026, that the registration statement became effective that day, that the offering is expected to close on October 26, 2026 subject to customary conditions, and that Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-running managers, with LifeSci Capital acting as passive book-running manager. The company's own pricing release, issued from South San Francisco through GlobeNewswire, confirmed the 17,640,000 shares at $18.00, the roughly $317.5 million in gross proceeds and the 30-day greenshoe of 2,646,000 shares.

The pre-IPO register was dominated by specialist healthcare investors. IPOScoop reported that Versant Ventures held an 18.9% stake before the offering, falling to 13.5% after it, Venrock Healthcare held 12.8% before and 9.2% after, and Redmile Biopharma held 11.1% before and 8.0% after, with RTW Investments, Janus Henderson and Blue Owl also listed as principal stockholders. The same report put the company's net loss for the 12 months ended June 30, 2026 at $30.03 million on collaboration revenue of $4.4 million, and described preliminary Phase 1 data from the first cohort of eight healthy atopic participants, two of them on placebo, in which LCA-0061 produced a mean maximum IgE reduction of 96% from baseline among those dosed.

Analysis

The most instructive detail in the first day of trading is not the size of the pop but the distance between the two numbers used to describe it. Reuters reported a 27.5% gain, a snapshot taken shortly after the opening print, while the session closed at $30.00 for a 66.67% advance, roughly two and a half times the intraday figure. What this really means is that the headline return on any given listing now depends heavily on the minute at which a reporter looks at the tape, and readers comparing coverage of the same event can come away with wildly different impressions of how hot the deal was. Here the gap is not a rounding difference but a spread of almost 40 percentage points, and the closing figure is the one that reflects what buyers were actually willing to pay by the bell.

The pricing itself looks deliberately conservative. Lycia and its bankers took the deal at the very top of the $16.00 to $18.00 range and upsized it, which signals that demand was strong enough to clear the book comfortably, yet they still left a very wide first day gain on the table. Selling 17,640,000 shares at $18.00 raised about $317.5 million; selling the same number at the $30.00 close would have raised roughly $529 million. For a company whose net loss for the 12 months ended June 30, 2026 was $30.03 million on collaboration revenue of $4.4 million, the foregone proceeds are not trivial, although the standard explanation is that the underwriters were buying durability rather than optimising a single print.

The bigger picture here is that the market is paying for platform credibility and early clinical signal rather than for a late-stage asset with an approved product. Lycia has no revenue-generating drug, its collaboration revenue of $4.4 million is modest, and its lead asset is in Phase 1 in a first cohort of eight healthy atopic participants, two on placebo, with a mean maximum IgE reduction of 96%. That is a striking number from a very small sample of healthy volunteers, not from patients with food allergy, and the full Phase 1 programme for LCA-0061 still has to establish what happens over repeated dosing and in people who actually have the disease. A $1.65 billion market value at the close is a judgment on the LYTAC platform and on Bertozzi's scientific standing as much as on a single cohort of healthy volunteers.

The shareholder register supports a second reading, that this is an institutional healthcare deal rather than a retail frenzy. Versant Ventures at 13.5% after the offering, Venrock Healthcare at 9.2% and Redmile Biopharma at 8.0% are the sort of long-only and crossover holders that typically anchor biotech books, and the involvement of Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities as joint bookrunners, with LifeSci Capital in a passive book-running role, points to a syndicate built for specialist accounts. The first day volume of about 2.28 million shares is only a fraction of the 17.64 million sold, which suggests that the pop came from a thin float and strong demand rather than from a wide trading crowd flipping stock.

Why It Matters

The listing matters because it tests the proposition that the autumn 2026 window genuinely favours biotechnology. Reuters said the window has been dominated by biotech while higher borrowing costs and unstable markets held back other sectors, and that it has also included heavily publicised postponements as investors became more selective. A deal that prices at the top of its range, upsizes by 27% and then closes 66.67% above its offer price is the strongest possible counter to the selectivity narrative, at least for a company with a Nobel laureate's name attached to its science and a platform story that investors can describe in a sentence.

It also matters for the protein degradation field more broadly. Lycia is one of a small group of companies pursuing extracellular degradation, and its ability to raise roughly $317.5 million on a Phase 1 pipeline is a signal that public investors are willing to fund mechanistic novelty. The company says the proceeds will fund clinical trials, which means the next leg of the story will be clinical data rather than financing news. For a sector that has spent several years consolidating and cutting headcount, a first day close near $1.65 billion for a company with a $30.03 million annual loss is a notable data point.

Finally, the structure of the deal matters for founders and venture backers. Versant Ventures, Venrock Healthcare and Redmile Biopharma all saw their stakes diluted by the offering, from 18.9% to 13.5%, 12.8% to 9.2% and 11.1% to 8.0% respectively, exactly as the arithmetic demands, and they accepted that dilution in exchange for a Nasdaq currency and a public valuation. That is the standard bargain of the biotech IPO, but it is worth remembering that the fully diluted valuation at pricing was $1.1 billion, which means the effective entry price for new buyers is far above the headline offer price once the greenshoe and options are counted.

Next Up

The immediate calendar item is the closing of the offering, which Lycia expects on October 26, 2026 subject to customary conditions. The underwriters then have 30 days to decide whether to exercise their option on up to 2,646,000 additional shares at the IPO price less discounts and commissions, a decision that typically lands within days of the close and would add roughly $47.6 million in gross proceeds if taken in full. Watch the aftermarket above the $28.55 opening print and the $30.00 close, since a hold above those levels would signal that the first day was not simply a thin float effect.

The larger test arrives with clinical news. LCA-0061 continues in Phase 1 in participants with elevated IgE including food allergy patients, LCA-0062 is in IND-enabling activities, and LCA-0321 is in Phase 1 in Graves' disease patients with a design aimed at degrading thyroid-stimulating hormone receptor autoantibodies. Any of those programmes reporting data would be a far more meaningful signal for the roughly $1.65 billion market value than the volume and price action of a single Friday session.